Form 8-K - Current report:
SEC Accession No. 0001753926-25-000585
Filing Date
2025-04-07
Accepted
2025-04-07 06:05:16
Documents
17
Period of Report
2025-04-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084763_8k.htm   iXBRL 8-K 45453
2 EXHIBIT 5.1 g084763_ex5-1.htm EX-5.1 9822
3 EXHIBIT 10.1 g084763_ex10-1.htm EX-10.1 261069
4 GRAPHIC image_001.jpg GRAPHIC 6241
5 GRAPHIC image_002.jpg GRAPHIC 1753
  Complete submission text file 0001753926-25-000585.txt   563311

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lipo-20250407.xsd EX-101.SCH 3012
7 XBRL LABEL FILE lipo-20250407_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE lipo-20250407_pre.xml EX-101.PRE 22357
19 EXTRACTED XBRL INSTANCE DOCUMENT g084763_8k_htm.xml XML 3703
Mailing Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208
Business Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208 412-901-0315
LIPELLA PHARMACEUTICALS INC. (Filer) CIK: 0001347242 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41575 | Film No.: 25816261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)